本轮融资由TCGX和ARCH Venture Partners共同领投,多家顶级医疗健康机构投资者参与 融资所得将用于支持潜在同类最佳VEGF/Ang2双特异性抗体IBI324(Ollin研发代号:OLN324)的全球III期临床研究,针对全球约150亿美元的视网膜治疗市场,以应对导致视力丧失的主要眼病 今年初OLN324在一项随机头对头临床Ib期概念验证(Proof of Concept)研究(...
Source Link本轮融资由TCGX和ARCH Venture Partners共同领投,多家顶级医疗健康机构投资者参与 融资所得将用于支持潜在同类最佳VEGF/Ang2双特异性抗体IBI324(Ollin研发代号:OLN324)的全球III期临床研究,针对全球约150亿美元的视网膜治疗市场,以应对导致视力丧失的主要眼病 今年初OLN324在一项随机头对头临床Ib期概念验证(Proof of Concept)研究(...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.